Literature DB >> 23456517

Disaccharides in the treatment of hepatic encephalopathy.

Praveen Sharma1, Barjesh Chander Sharma.   

Abstract

Management of hepatic encephalopathy (HE) primarily involves avoidance of precipitating factors and administration of various ammonia-lowering therapies such as nonabsorbable disaccharides and antimicrobial agents like rifaximin. The nonabsorbable disaccharides which include lactulose and lactitol are considered the first-line therapy for the treatment of HE and minimal hepatic encephalopathy (MHE). Lactulose significantly improves cognitive function and health-related quality of life in patients with MHE. Lactitol is comparable to lactulose in the treatment of HE with fewer side effects. Lactulose has also shown to be effective in primary and secondary prophylaxis of HE. Disaccharides were found to be comparable to rifaximin in recent systemic reviews in the treatment of HE however conclusion was based on inclusion of some poor quality trials. Combination therapy of disaccharides either with rifaximin, L-ornithine L-aspartate,probiotics for the treatment of HE needs further validation in large studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23456517     DOI: 10.1007/s11011-013-9392-4

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  63 in total

Review 1.  Probiotics for patients with hepatic encephalopathy.

Authors:  Richard G McGee; Anouk Bakens; Kerrie Wiley; Stephen M Riordan; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

2.  Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.

Authors:  Antoni Mas; Juan Rodés; Lourdes Sunyer; Luís Rodrigo; Ramon Planas; Victor Vargas; Lluís Castells; Dolores Rodríguez-Martínez; Conrado Fernández-Rodríguez; Ignasi Coll; Albert Pardo
Journal:  J Hepatol       Date:  2003-01       Impact factor: 25.083

3.  A controlled clinical trial of lactulose in hepatic encephalopathy.

Authors:  F Simmons; H Goldstein; J D Boyle
Journal:  Gastroenterology       Date:  1970-12       Impact factor: 22.682

4.  Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose.

Authors:  Praveen Sharma; Amit Agrawal; Barjesh C Sharma; Shiv K Sarin
Journal:  J Gastroenterol Hepatol       Date:  2011-06       Impact factor: 4.029

5.  Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial.

Authors:  M Y Morgan; K E Hawley
Journal:  Hepatology       Date:  1987 Nov-Dec       Impact factor: 17.425

6.  Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy.

Authors:  M Romero-Gómez; F Boza; M S García-Valdecasas; E García; J Aguilar-Reina
Journal:  Am J Gastroenterol       Date:  2001-09       Impact factor: 10.864

7.  Rifaximin for the treatment of hepatic encephalopathy.

Authors:  Kevin Mullen; Ravi Prakash
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2010-12       Impact factor: 3.869

8.  Profile of hepatic encephalopathy in children with cirrhosis and response to lactulose.

Authors:  Praveen Sharma; Barjesh C Sharma
Journal:  Saudi J Gastroenterol       Date:  2011 Mar-Apr       Impact factor: 2.485

9.  Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.

Authors:  Barjesh Chander Sharma; Praveen Sharma; Amit Agrawal; Shiv Kumar Sarin
Journal:  Gastroenterology       Date:  2009-06-06       Impact factor: 22.682

10.  Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy.

Authors:  Carroll B Leevy; James A Phillips
Journal:  Dig Dis Sci       Date:  2007-03       Impact factor: 3.487

View more
  10 in total

1.  Can functional parameters from hepatobiliary phase of gadoxetate MRI predict clinical outcomes in patients with cirrhosis?

Authors:  Kumar Sandrasegaran; Enming Cui; Reem Elkady; Pauley Gasparis; Gitasree Borthakur; Mark Tann; Suthat Liangpunsakul
Journal:  Eur Radiol       Date:  2018-04-12       Impact factor: 5.315

Review 2.  Probiotics for people with hepatic encephalopathy.

Authors:  Rohan Dalal; Richard G McGee; Stephen M Riordan; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2017-02-23

Review 3.  Evidence-based approach to management of hepatic encephalopathy in adults.

Authors:  Gilles Jadd Hoilat; Fathima Keshia Suhail; Talal Adhami; Savio John
Journal:  World J Hepatol       Date:  2022-04-27

4.  Management of hepatic encephalopathy.

Authors:  Jennifer A Frontera
Journal:  Curr Treat Options Neurol       Date:  2014-06       Impact factor: 3.598

5.  Carbon Tetrachloride Increases the Pro-inflammatory Cytokines Levels in Different Brain Areas of Wistar Rats: The Protective Effect of Acai Frozen Pulp.

Authors:  Fernanda de Souza Machado; Jéssica Pereira Marinho; Ana Lúcia Abujamra; Caroline Dani; André Quincozes-Santos; Cláudia Funchal
Journal:  Neurochem Res       Date:  2015-08-18       Impact factor: 3.996

6.  RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.

Authors:  Christian Schulz; Kerstin Schütte; Siegfried Kropf; Friedhelm C Schmitt; Riccardo Vasapolli; Leon M Kliegis; Antonia Riegger; Peter Malfertheiner
Journal:  Trials       Date:  2016-02-29       Impact factor: 2.279

7.  Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis.

Authors:  Ying-Chi Shen; Ya-Hui Chang; Ching-Ju Fang; Yang-Sheng Lin
Journal:  Nutr J       Date:  2019-07-06       Impact factor: 3.271

8.  Unexplained Fatal Hyperammonemia in a Patient With New Diagnosis of Acute Monoblastic Leukemia.

Authors:  Mohamed Fayed; Nimesh Patel; Yahia Al Turk; Patrick B Bradley
Journal:  Cureus       Date:  2021-12-02

9.  Lactulose enhances neuroplasticity to improve cognitive function in early hepatic encephalopathy.

Authors:  Nan Yang; He Liu; Yao Jiang; Ji Zheng; Dong-Mei Li; Chao Ji; Yan-Yong Liu; Ping-Ping Zuo
Journal:  Neural Regen Res       Date:  2015-09       Impact factor: 5.135

10.  Microbiota stability in healthy individuals after single-dose lactulose challenge-A randomized controlled study.

Authors:  Sandra Y Wotzka; Markus Kreuzer; Lisa Maier; Mirjam Zünd; Markus Schlumberger; Bidong Nguyen; Mark Fox; Daniel Pohl; Henriette Heinrich; Gerhard Rogler; Luc Biedermann; Michael Scharl; Shinichi Sunagawa; Wolf-Dietrich Hardt; Benjamin Misselwitz
Journal:  PLoS One       Date:  2018-10-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.